AR053651A1 - Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama - Google Patents

Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama

Info

Publication number
AR053651A1
AR053651A1 ARP050104588A ARP050104588A AR053651A1 AR 053651 A1 AR053651 A1 AR 053651A1 AR P050104588 A ARP050104588 A AR P050104588A AR P050104588 A ARP050104588 A AR P050104588A AR 053651 A1 AR053651 A1 AR 053651A1
Authority
AR
Argentina
Prior art keywords
antibody
breast cancer
aromatase inhibitor
ctla4
antictla4
Prior art date
Application number
ARP050104588A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR053651A1 publication Critical patent/AR053651A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
ARP050104588A 2004-11-04 2005-11-02 Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama AR053651A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04

Publications (1)

Publication Number Publication Date
AR053651A1 true AR053651A1 (es) 2007-05-16

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104588A AR053651A1 (es) 2004-11-04 2005-11-02 Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama

Country Status (15)

Country Link
EP (1) EP1819735A1 (de)
JP (1) JP2008518902A (de)
KR (1) KR20070067702A (de)
CN (1) CN101052655A (de)
AR (1) AR053651A1 (de)
AU (1) AU2005300315A1 (de)
BR (1) BRPI0515735A2 (de)
CA (1) CA2586844A1 (de)
IL (1) IL182244A0 (de)
MX (1) MX2007003804A (de)
NO (1) NO20072576L (de)
RU (1) RU2007114111A (de)
TW (1) TW200621804A (de)
WO (1) WO2006048749A1 (de)
ZA (1) ZA200702577B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EA027693B1 (ru) 2008-09-26 2017-08-31 Токаджен Инк. Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
WO2010040105A2 (en) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
EP2710137B1 (de) 2011-03-10 2018-09-19 Provectus Pharmatech, Inc. Eine kombination aus bengalrosa und anti-ctla4 antikörper zur behandlung von krebs
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN103768596B (zh) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的组合产品、其用途及相关方法
CN104884627A (zh) 2012-10-25 2015-09-02 托卡根公司 具有小型启动子盒的逆转录病毒载体
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
EP3057990B1 (de) * 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Zusammensetzungen mit einer kombination aus einem vegf-antagonisten und einem anti-ctla-4-antikörper
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
EA201890640A1 (ru) 2015-09-04 2018-09-28 Токаджен Инк. Рекомбинантные векторы, содержащие пептид 2а
CN106883298B (zh) * 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 双特异性偶联抗体及其制法和用途
SG11201805835WA (en) 2016-01-08 2018-08-30 Replimune Ltd Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
WO2021173870A1 (en) * 2020-02-27 2021-09-02 University Of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
TW200621804A (en) 2006-07-01
CN101052655A (zh) 2007-10-10
MX2007003804A (es) 2007-04-23
ZA200702577B (en) 2008-07-30
IL182244A0 (en) 2007-09-20
CA2586844A1 (en) 2006-05-11
RU2007114111A (ru) 2008-12-10
NO20072576L (no) 2007-08-03
WO2006048749A1 (en) 2006-05-11
KR20070067702A (ko) 2007-06-28
BRPI0515735A2 (pt) 2011-10-11
JP2008518902A (ja) 2008-06-05
AU2005300315A1 (en) 2006-05-11
EP1819735A1 (de) 2007-08-22

Similar Documents

Publication Publication Date Title
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR109461A2 (es) Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento
AR054237A1 (es) Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
CR8603A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
AR087790A1 (es) Uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2008002466A1 (es) Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado.
CO6280488A2 (es) Combinacion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal